Hyperkalemia during Treatment with HMG-CoA Reductase Inhibitor

S. Edelman, J. L. Witztum, Scott M Grundy

Research output: Contribution to journalLetter

11 Scopus citations

Abstract

To the Editor: We recently observed a case of severe hyperkalemia in a patient with long-standing Type I diabetes, hypertension, and hyperlipidemia treated with lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and lisinopril, an angiotensin-converting enzyme inhibitor. The patient was a 33-year-old white male physician with familial hypercholesterolemia, Type I diabetes mellitus since the age of 15, mild renal insufficiency with base-line creatinine and potassium levels of 1.7 mg per deciliter and 5.3 to 5.6 mmol per liter, respectively, and hypertension well controlled with lisinopril (50 mg per day). His base-line low-density lipoprotein (LDL) cholesterol level was 189 mg…

Original languageEnglish (US)
Pages (from-to)1219-1220
Number of pages2
JournalNew England Journal of Medicine
Volume320
Issue number18
DOIs
StatePublished - May 4 1989

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Hyperkalemia during Treatment with HMG-CoA Reductase Inhibitor'. Together they form a unique fingerprint.

  • Cite this